Neumeier Poma Investment Counsel LLC Harmony Biosciences Holdings, Inc. Transaction History

Neumeier Poma Investment Counsel LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$31.89 - $39.03 $1.3 Million - $1.59 Million	-40,750 Reduced 6.4%	595,490 $19.5 Million
Q2 2023 Aug 10, 2023	SELL	$30.5 - $37.4 $1.3 Million - $1.59 Million	-42,475 Reduced 6.26%	636,240 $22.4 Million
Q1 2023 May 10, 2023	SELL	$30.8 - $53.92 $204,050 - $357,220	-6,625 Reduced 0.97%	678,715 $22.2 Million
Q4 2022 Feb 10, 2023	BUY	$45.4 - $60.91 $2.22 Million - $2.98 Million	48,855 Added 7.68%	685,340 $37.8 Million
Q3 2022 Nov 09, 2022	BUY	$42.06 - $55.45 $10.5 Million - $13.9 Million	250,170 Added 64.76%	636,485 $28.2 Million
Q2 2022 Aug 10, 2022	BUY	$33.54 - $52.15 $13 Million - $20.1 Million	386,315 New	386,315 $18.8 Million

246

45.5M

108K

49.2K

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.29B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

Get notified when there are updates to the investment portfolio of Neumeier Poma Investment Counsel LLC, based on Form 13F filings with the SEC.

Stay updated on Neumeier Poma Investment Counsel LLC with notifications on news.